Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

This was the stock's fourth consecutive day of losses.

The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology. With over 25 years in healthcare ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other ...

We recently compiled a list of the Top 20 Dividend Stocks of 2024. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other dividend stocks.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other dividend stocks. Macroeconomic factors have weighed on US stocks in the final ...